Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays
Open accessThe DOI matches its Crossref record; 309 of the 334 references it cites were found in a registry or an index; 163 of the 299 sources its claims cite were checked for support.
Abstract
Inherited retinal dystrophies and optic neuropathies cause chronic disabling loss of visual function. The development of recombinant adeno-associated viral vectors (rAAV) gene therapies in all disease fields have been promising, but the translation to the clinic has been slow. The safety and efficacy profiles of rAAV are linked to the dose of applied vectors. DNA changes in the rAAV gene cassette affect potency, the expression pattern (cell-specificity), and the production yield. Here, we present a library of rAAV vectors and elements that provide a workflow to design novel vectors. We first performed a meta-analysis on recombinant rAAV elements in clinical trials (2007–2020) for ocular gene therapies. We analyzed 33 unique rAAV gene cassettes used in 57 ocular clinical trials. The rAAV gene therapy vectors used six unique capsid variants, 16 different promoters, and six unique polyadenylation sequences. Further, we compiled a list of promoters, enhancers, and other sequences used in current rAAV gene cassettes in preclinical studies. Then, we give an update on pro-viral plasmid backbones used to produce the gene therapy vectors, inverted terminal repeats, production yield, and rAAV safety considerations. Finally, we assess rAAV transgene and bioactivity assays applied to cells or organoids in vitro, explants ex vivo, and clinical studies.
Overview
CoChat Summary
TL;DR
This review/meta-analysis catalogs recombinant AAV vector elements used in ocular gene therapy clinical trials (2007–2020) and preclinical assays, analyzing 33 unique rAAV gene cassettes from 57 trials. It provides a workflow/library of capsids, promoters, enhancers, introns, polyadenylation sequences, production considerations, and transgene/bioactivity assay models for designing ocular rAAV vectors.
Key findings
- The meta-analysis identified 33 unique rAAV gene cassettes used in 57 ocular clinical trials; these used six unique capsid variants, 16 different promoters, and six unique polyadenylation sequences.
- Five different AAV-RPE65 products were tested in 13 clinical trials, leading to the first retinal gene therapy approved by the FDA in December 2017 and EMA in November 2018 (AAV-hRPE65v2; voretigene neparvovec-rzyl, LUXTURNA).
- The review compiles vector elements including capsids, ubiquitous and cell-specific promoters, enhancers, introns, WPRE, polyadenylation sequences, pro-viral plasmid backbones, ITRs, and production platforms; it notes rAAV packaging capacity of about 4.5–4.6 kb excluding ITRs, while scAAV reduces capacity to a maximum of 2.5 kb including ITRs.
- Assay models reviewed include in vitro cell lines, hiPSC-derived RPE, retinal organoids, ex vivo human retina, and in vivo/NHP studies; NHP and human retinal explants matched more closely (correlation r = 0.66–0.67) than mouse/human comparisons (r = 0.24–0.32).
Methods
- Meta-analysis: clinical trial identifiers were collected from reviews on ocular gene therapy, then searched on clinicaltrials.gov using keywords including AAV, gene therapy, retinitis pigmentosa, RP, Leber congenital amaurosis, LCA, AMD, and CHM, with last search date 01 April 2020; the search was limited to ocular gene therapies and cross-checked against news, reviews, Ph.D. theses, patents, SEC filings, company websites, presentations, and conference abstracts.
- The 33 unique rAAV ocular gene therapy products were analyzed for prokaryotic plasmid backbone, ITR AAV serotype, enhancers, promoters, introns, cDNA genes, codon optimization, human or other species-related sequences, post-transcriptional stabilizing sequences, polyadenylation sequences, and rAAV production platform; missing information was indicated as “UntoldR” or “?”.
- The paper also compiles preclinical promoters, enhancers, and other sequences and reviews transgene expression assays and biological activity assays across in vitro, ex vivo, and in vivo models.
Limitations
- The paper states that many papers on rAAV ocular trials do not sufficiently describe the elements on the plasmid used for viral vector production, including bacterial origin and bacterial selection markers, and that poor description and the vast expanse of rAAV vectors make fair comparison of vector elements very challenging.
- The paper states that large-scale comparative rAAV element studies are missing in ophthalmology; it also notes that rAAV integration studies in the retina are underrepresented and that almost no rAAV study specifically investigated rAAV integration events.
- Evident from the text: as a review/meta-analysis, it does not report new primary experimental data, and missing or incomplete source information is marked as “UntoldR” or “?”, indicating reliance on secondary and sometimes incomplete public/company documentation.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



![Figure 4 How to assess Inverted Terminal Repeats (ITRs) of rAAV and how they allow concatemerization. (A) Restriction enzyme sites in the AAV serotype 2 ITR in the flop configuration. RBE’/RBE binds Rep68 (RBE, Rep-binding element) and initiates the Rep helicase. The Rep helicase nicks the trs (terminal resolution site). Restriction enzyme recognition site indicated in blue and the actual cut in red. Figure adapted from [238]. (B) ITR structure in the nucleus after second-strand DNA synthesis in dividing cells favoring homologous recombination. Most rAAV-vectors form episomal concatemeric circular double-stranded DNA.](https://figures.cochat.ai/paper-figures/d2cf029bfc5c418988eb657099b1a410/recombinant-adeno-associated-viral-vectors-raav-vector-elements-in-ocular-gene-figure-4.jpg)
![Figure 5 A hypothetical model of the spread of rAAV capsids (serotypes 1, 2, 5 8, and 9) after intravitreal or subretinal injection in disease or non-disease mouse retinas in vivo based on the studies [99,294,304,306,308,309]. RPE, retinal pigment epithelium; OLM, outer limiting membrane, ONL, outer nuclear layer; OPL, outer plexiform layer; INL, inner nuclear layer; GCL, ganglion cell layer; ILM, Inner Limiting Membrane.](https://figures.cochat.ai/paper-figures/e3f5847ede504cb38d2d032ab640db72/recombinant-adeno-associated-viral-vectors-raav-vector-elements-in-ocular-gene-figure-5.jpg)

Verification
Claims the paper makes
109 Valid · 57 Not valid · 98 Not checked · 102 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Relative tissue-specific expression of two gRNAs for CRISPR/Cas gene editing in myotubes was achieved by linking a muscle-specific MHCK7 promoter (pol II) with gRNA-linked self-cleaving ribozyme sequences derived of Hepatitis delta virus (HDV) and a Hammerhead (HH) sequence [134-137].”
§ Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays > 3.5. Small Nuclear RNA (snRNA) Promoters
What the sources say
- Partly supportedcites [134] Eckenfelder, 2012, The Cellular Processing Capacity Limits the Amounts of Chimeric U7 snRNA Available for Antisense Delivery, Mol. Ther. Nucleic Acids sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Not checked — no full text of the sourcecites [135] Salva, 2007, Design of tissue-specific regulatory cassettes for high-level rAAV-mediated expression in skeletal and cardiac muscle, Mol. Ther. source
- Disputedcites [136] LaVail, 2000, Ribozyme rescue of photoreceptor cells in P23H transgenic rats: Long-term survival and late-stage therapy, Proc. Natl. Acad. Sci. USA sourceExperimental — accuracy not yet measured
The Abstract (page unavailable) describes a different construct: rAAV vectors used a proximal bovine rod opsin promoter to express hairpin or hammerhead ribozymes in rat photoreceptors. Those ribozymes targeted mutant rhodopsin transcripts; the paper does not describe MHCK7-driven, HDV/hammerhead-flanked CRISPR gRNAs in myotubes. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Supportedcites [137] Xu, L., Zhao, L., Gao, Y., Xu, J., and Han, R. (2017). Empower multiplex cell and tissue-specific CRISPR-mediated gene manipulation with self-cleaving ribozymes and tRNA. Nucleic Acids Res., 45. source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“However, if left active in cells, functional rAAV-CRISPR/Cas9 systems do increase the number of off-target integration events into the genome [218].”
§ Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays > 4.3. rAAV-Vectors Expressing CRISPR/Cas
What the sources say
- Disputedcites [218] Hanlon, K.S., Kleinstiver, B.P., Garcia, S.P., Zaborowski, M.P., Volak, A., Spirig, S.E., Muller, A., Sousa, A.A., Tsai, S.Q., and Bengtsson, N.E. (2019). High levels of AAV vector integration into CRISPR-induced DNA breaks. Nat. Commun., 10. sourceExperimental — accuracy not yet measured
The Results (Genome-wide AAV mapping from mouse brain) report no increase in the overall number of integration sites when Cas9 and gRNA were both present, and say integration at predicted off-target cut sites was below detection. The Discussion likewise reports no significant increase in overall AAV integration with Cas9; the increase was at CRISPR target sites, not off-target sites. The paper raises sustained nuclease activity as a potential concern but does not report the claimed off-target increase. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Because of the relatively large size of 4277 bp of dCas9-VPR cDNA, the authors used a dual rAAV system to express the dCas9-VPR and gRNA expression cassettes [223,224].”
§ Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays > 4.3. rAAV-Vectors Expressing CRISPR/Cas
What the sources say
- Disputedcites [223] Kocak, 2013, RNA-guided gene activation by CRISPR-Cas9-based transcription factors, Nat. Methods sourceExperimental — accuracy not yet measured
The paper’s Online Methods (Plasmids; Cell culture and transfection, page unavailable) describe a dCas9-VP64 construct and transfection of plasmids encoding dCas9-VP64 and gRNAs, not a dual rAAV system expressing dCas9-VPR. Our copy does not give a 4277-bp dCas9-VPR cDNA size or attribute the delivery method to that size. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Disputedcites [224] Konermann, 2015, Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex, Nature sourceExperimental — accuracy not yet measured
The Extended Data Figure 7 caption describes three lentiviral vectors expressing sgRNA, dCas9-VP64, and MS2-p65-HSF1, not a dual rAAV system expressing dCas9-VPR and gRNA. The genome-scale gene activation screen section likewise identifies the delivery system as lentiviral. These passages do not give a 4277-bp dCas9-VPR cDNA size. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“The hypoxia-induced Müller glial specific promoter showed no luciferase expression in HEK293, C6, HT22, and ARPE19 cells [97].”
§ Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays > 5.1. In Vitro Immortalized Epithelial Cell Lines for Transgene and Bioactivity Assays
What the sources say
- Disputedcites [97] Prentice, 2011, Hypoxia-regulated retinal glial cell-specific promoter for potential gene therapy in disease, Investig. Ophthalmol. Vis. Sci. sourceExperimental — accuracy not yet measured
The Figure 4 caption says the regulated promoter had basal or minimal expression in HEK, C6, HT22, and ARPE-19 cells, not no expression. The Hypoxic Induction and Cell Specificity section reports no hypoxic induction in those lines; that does not establish an absence of luciferase expression. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“The ubiquitous UbC promoter showed no toxicity to the mouse RPE [324].”
§ Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays > 5.6.4. Cis-Regulatory Toxicity of rAAV Vectors In Vivo?
What the sources say
- Disputedcites [324] Xiong, 2019, AAV cis-regulatory sequences are correlated with ocular toxicity, Proc. Natl. Acad. Sci. USA sourceExperimental — accuracy not yet measured
The Results section on RPE toxicity says the broadly active UbiC promoter induced strong RPE toxicity, the opposite of the claim. The study used subretinal AAV injections in mice, as described in the Results section on photoreceptor toxicity. (LLM, conf=0.95)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
203 more claims · 84 with their cited sources checked
Create a free account to see all 366 claims and to verify the 4 references still open.
- It may state two separate claims as one. 107
- Probably not a substantial claim. 78
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The immune reactions include induction of neutralizing antibodies that reduce the number of capsids reaching the target cells, innate immune pathways silencing the gene cassette within the host cell, and cell-mediated T-cell immune responses against foreign protein expression.”
From Ocular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses (2022) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Unlike adenoviruses, AAVs generate relatively mild innate and adaptive immune responses, which allow for stable long-term transgene expression.”
From Ocular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses (2022) · cites this paper as [18]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Since then, AAV-mediated gene delivery into the retina has been used in several proof-of-concept studies to target photoreceptors or the RPE in mice and larger models (such as dogs) [63,64,65].”
From The Ocular Gene Delivery Landscape (2021) · cites this paper as [63]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays > 2. Ocular rAAV Vector-Based Therapies in Clinical Trials
“a promoter shortened to 750 bp (NA65p)”
§ Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays > 7.1. A Meta-Analysis on Pro-Viral Plasmids and Production Platforms for Ocular rAAV Therapies in Clinical Trials
“| NA65p | 1383 |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays > Additional information
“Lentiviral products, cell therapy products, antibodies, and antisense oligonucleotide (AONs) products were removed from Figure 3 and Table 1 to include only rAAV-based therapies.”
§ Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays > 7.1. A Meta-Analysis on Pro-Viral Plasmids and Production Platforms for Ocular rAAV Therapies in Clinical Trials
“| Usher | | UshStat | EIAV | CMV | | WPRE | MYO7A | SIN-LTR | HEK293 | | Usher | | QR-421a | | | | AON-USH2A | | | Synthetic |”
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“Sun, 2010, Gene therapy with a promoter targeting both rods and cones rescues retinal degeneration caused by AIPL1 mutations, Gene Ther., 17, 117, 10.1038/gt.2009.104”
Cited work 10.1038/gt.2009.104 · retracted 2024-11-15 · notice 10.1038/s41434-024-00505-6 · this paper published 2020-06-12
Citations
Cites
1 retracted
Sun, X., Pawlyk, B., Xu, X., Liu, X., Bulgakov, O. V., Adamian, M., Sandberg, M. A., Khani, S. C., Tan, M.-H., Smith, A. J., et al. (2010) · Gene Therapy · doi:10.1038/gt.2009.104 · Cited by 123
RetractedEfficient selection for high-expression transfectants with a novel eukaryotic vector
Hitoshi, N., Ken-ichi, Y., & Jun-ichi, M. (1991) · Gene · doi:10.1016/0378-1119(91)90434-d · Cited by 5,134
Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex
Konermann, S., Brigham, M. D., Trevino, A. E., Joung, J., Abudayyeh, O. O., Barcena, C., Hsu, P. D., Habib, N., Gootenberg, J. S., Nishimasu, H., et al. (2015) · Nature · doi:10.1038/nature14136 · Cited by 2,825 · cited 1×
“Because of the relatively large size of 4277 bp of dCas9-VPR cDNA, the authors used a dual rAAV system to express the dCas9-VPR and gRNA expression cassettes [223,224].”
BackgroundAdeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924 · cited 1×
“Dose finding studies have shown that a high number of rAAV particles (>1012 viral genomes (vg)) can give rise to transient inflammation in mice [35].”
BackgroundSTEROID RECEPTOR REGULATED TRANSCRIPTION OF SPECIFIC GENES AND GENE NETWORKS
Yamamoto, K. R. (1985) · Annual Review of Genetics · doi:10.1146/annurev.ge.19.120185.001233 · Cited by 1,872 · cited 1×
“Active when glucocorticoids or progestins present [175,176]”
Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways
Grimm, D., Streetz, K. L., Jopling, C. L., Storm, T. A., Pandey, K., Davis, C. R., Marion, P., Salazar, F., & Kay, M. A. (2006) · Nature · doi:10.1038/nature04791 · Cited by 1,677 · cited 1×
“Cellular toxicity can, for example, be observed in rAAV shRNA overexpression studies in which ubiquitous promoters were used that caused saturation of cellular miRNA pathways [88].”
BackgroundDynan, W. S., & Tjian, R. (1983) · Cell · doi:10.1016/0092-8674(83)90210-6 · Cited by 1,445 · cited 1×
“For example, the transactional activation of the widely used CMV or early SV40 promoters is related to the binding of the ubiquitous transcription factors Sp1/Sp3 [92,93].”
MethodPurification and biochemical characterization of the promoter-specific transcription factor, Sp1
Briggs, M. R., Kadonaga, J. T., Bell, S. P., & Tjian, R. (1986) · Science · doi:10.1126/science.3529394 · Cited by 1,435 · cited 1×
“Moreover, most mammalian cells express the Sp1 transcription factor [94].”
BackgroundConvection-enhanced delivery of macromolecules in the brain.
Bobo, R. H., Laske, D. W., Akbasak, A., Morrison, P. F., Dedrick, R. L., & Oldfield, E. H. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.6.2076 · Cited by 1,415 · cited 1×
“MVM Ubiquitous, ++ [54,67] MeCP2 229 ubiquitous [68] CMV 800 Ubiquitous, ++, prone to silencing [54] shCMV 220 Ubiquitous, ++ [24]”
Kim, J. H., Lee, S.-R., Li, L.-H., Park, H.-J., Park, J.-H., Lee, K. Y., Kim, M.-K., Shin, B. A., & Choi, S.-Y. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018556 · Cited by 1,338 · cited 1×
“Miscellaneous Size Description References 2A 75 Self-cleaving linker [159]”
BackgroundRNA-guided gene activation by CRISPR-Cas9-based transcription factors
Perez-Pinera, P., Kocak, D. D., Vockley, C. M., Adler, A. F., Kabadi, A. M., Polstein, L. R., Thakore, P. I., Glass, K. A., Ousterout, D. G., Leong, K. W., et al. (2013) · Nature Methods · doi:10.1038/nmeth.2600 · Cited by 1,328 · cited 1×
“Because of the relatively large size of 4277 bp of dCas9-VPR cDNA, the authors used a dual rAAV system to express the dCas9-VPR and gRNA expression cassettes [223,224].”
Background(1984) · PubMed · Cited by 1,200
High-performance calcium sensors for imaging activity in neuronal populations and microcompartments
Dana, H., Sun, Y., Mohar, B., Hulse, B. K., Kerlin, A. M., Hasseman, J. P., Tsegaye, G., Tsang, A., Wong, A., Patel, R., et al. (2019) · Nature Methods · doi:10.1038/s41592-019-0435-6 · Cited by 1,182
A Designer AAV Variant Permits Efficient Retrograde Access to Projection Neurons
Tervo, D. G. R., Hwang, B.-Y., Viswanathan, S., Gaj, T., Lavzin, M., Ritola, K. D., Lindo, S., Michael, S., Kuleshova, E., Ojala, D., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.09.021 · Cited by 1,179
Living on a break: cellular senescence as a DNA-damage response
d'Adda di Fagagna, F. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2440 · Cited by 1,170
The RNA Polymerase II Core Promoter
Smale, S. T., & Kadonaga, J. T. (2003) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.72.121801.161520 · Cited by 1,133 · cited 2×
“, ~35-bp upstream positioned TATA/CAAT/GC-box sequence) [45].”
BackgroundTherapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges
Mingozzi, F., & High, K. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2988 · Cited by 893 · cited 1×
“This immune cascade model might explain why re-administration in patients could become difficult, and why the administration of rAAVs in patients with high neutralizing antibodies (nAbs) are generally not included in clinical trials [327].”
BackgroundEmerging issues in AAV-mediated in vivo gene therapy
Colella, P., Ronzitti, G., & Mingozzi, F. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.11.007 · Cited by 881
Glia–neuron interactions in the mammalian retina
Vecino, E., Rodriguez, F. D., Ruzafa, N., Pereiro, X., & Sharma, S. C. (2016) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2015.06.003 · Cited by 825
MacLaren, R. E., Groppe, M., Barnard, A. R., Cottriall, C. L., Tolmachova, T., Seymour, L., Clark, K. R., During, M. J., Cremers, F. P. M., Black, G. C. M., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62117-0 · Cited by 796
McCarty, D., Monahan, P., & Samulski, R. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301514 · Cited by 735 · cited 1×
“ScAAV mediated transgene expression could be enhanced by 5 up to 140 fold in vitro [254], and a further 90% increase in the yield of dimeric genomes was be achieved by deletion of the terminal resolution site sequence from one ITR (ITR2Δ) [255].”
BackgroundIn vivo genome editing with a small Cas9 orthologue derived from Campylobacter jejuni
Kim, E., Koo, T., Park, S. W., Kim, D., Kim, K., Cho, H.-Y., Song, D. W., Lee, K. J., Jung, M. H., Kim, S., et al. (2017) · Nature Communications · doi:10.1038/ncomms14500 · Cited by 715 · cited 6×
“The downregulation was linked to a decrease in spot size on morphology of the laser-induced choroidal neovascularization (wet AMD model) but not on retinal function measured by electroretinogram (ERG)[221].”
BackgroundInfluentialDevelopment of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10
Maeder, M. L., Stefanidakis, M., Wilson, C. J., Baral, R., Barrera, L. A., Bounoutas, G. S., Bumcrot, D., Chao, H., Ciulla, D. M., DaSilva, J. A., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0327-9 · Cited by 707 · cited 2×
“A recent CRISPR/Cas9 study indicated that Cas9 breaks caused >1-20% insertion events of the rAAV cassette (EDIT-101) into the dsDNA break in the CEP290 intron in human retinal explant DNA, not counting integrations in other regions of the genome [250].”
BackgroundEngineering targeted viral vectors for gene therapy
Waehler, R., Russell, S. J., & Curiel, D. T. (2007) · Nature Reviews Genetics · doi:10.1038/nrg2141 · Cited by 687 · cited 1×
“However, many other potential technologies have been developed alongside, including exosomes/liposomes, antisense oligonucleotides (AONs), electroporation of naked DNA/RNA, or application of nanoparticles [12,13].”
BackgroundJacobson, S. G. (2012) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2011.298 · Cited by 639
Very mild muscular dystrophy associated with the deletion of 46% of dystrophin
England, S. B., Nicholson, L. V. B., Johnson, M. A., Forrest, S. M., Love, D. R., Zubrzycka-Gaarn, E. E., Bulman, D. E., Harris, J. B., & Davies, K. E. (1990) · Nature · doi:10.1038/343180a0 · Cited by 623 · cited 1×
“3 Mb; 79-exons; 3685 amino acids; 11,055 bp) do not rescue the Duchenne muscular dystrophy phenotype in muscle cells except for the microdystrophin for which was reported a milder clinical phenotype [183,184].”
BackgroundAschauer, D. F., Kreuz, S., & Rumpel, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076310 · Cited by 522 · cited 1×
“rAAV DNA carrier systems have been successfully used because they have a plethora of advantages: (1) They express the transgene within days or weeks and can reach full expression levels after 4–6 weeks in vivo [20,21].”
BackgroundSelf-complementary AAV vectors; advances and applications
McCarty, D. M. (2008) · Molecular Therapy · doi:10.1038/mt.2008.171 · Cited by 515 · cited 8×
“This basic rAAV gene delivery vector can consist of two inverted terminal repeats (ITRs) of the AAV serotype 2 (ITR2), a promoter, a wild-type copy of the cDNA of the gene-of-interest, as well as other enhancers or transcript stabilizing elements, an intron, and a polyadenylation sequence (Figure 2B).”
BackgroundInfluentialSystemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy
Duan, D. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.07.011 · Cited by 489 · cited 1×
“3 Mb; 79-exons; 3685 amino acids; 11,055 bp) do not rescue the Duchenne muscular dystrophy phenotype in muscle cells except for the microdystrophin for which was reported a milder clinical phenotype [183,184].”
BackgroundNakai, H., Yant, S. R., Storm, T. A., Fuess, S., Meuse, L., & Kay, M. A. (2001) · Journal of Virology · doi:10.1128/jvi.75.15.6969-6976.2001 · Cited by 478
Lundstrom, K. (2018) · Diseases · doi:10.3390/diseases6020042 · Cited by 469
Samulski, R. J., Berns, K. I., Tan, M., & Muzyczka, N. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.6.2077 · Cited by 466 · cited 1×
“The generation of the first recombinant AAV (rAAV2) was already described by the labs of Nick Muzyczka and Barrie Carter in 1982–1983 [37,38].”
BackgroundMcCown, T. J., Xiao, X., Li, J., Breese, G. R., & Jude Samulski, R. (1996) · Brain Research · doi:10.1016/0006-8993(95)01488-8 · Cited by 450
Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2
Qing, K., Mah, C., Hansen, J., Zhou, S., Dwarki, V., & Srivastava, A. (1999) · Nature Medicine · doi:10.1038/4758 · Cited by 443 · cited 1×
“For example, rAAV2 requires the FGFR1 receptor that can be blocked by FGF-2 supplementation [288].”
BackgroundHigh levels of AAV vector integration into CRISPR-induced DNA breaks
Hanlon, K. S., Kleinstiver, B. P., Garcia, S. P., Zaborowski, M. P., Volak, A., Spirig, S. E., Muller, A., Sousa, A. A., Tsai, S. Q., Bengtsson, N. E., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12449-2 · Cited by 431 · cited 1×
“However, if left active in cells, functional rAAV-CRISPR/Cas9 systems do increase the number of off-target integration events into the genome [218].”
BackgroundGray, S. J., Foti, S. B., Schwartz, J. W., Bachaboina, L., Taylor-Blake, B., Coleman, J., Ehlers, M. D., Zylka, M. J., McCown, T. J., & Samulski, R. J. (2011) · Human Gene Therapy · doi:10.1089/hum.2010.245 · Cited by 420 · cited 2×
“CMV 800 Ubiquitous, ++, prone to silencing [54]”
BackgroundAAV serotype 2 vectors preferentially integrate into active genes in mice
Nakai, H., Montini, E., Fuess, S., Storm, T. A., Grompe, M., & Kay, M. A. (2003) · Nature Genetics · doi:10.1038/ng1179 · Cited by 392 · cited 1×
“Yet, follow-up studies indicated that 53-62% of rAAV integrations in the liver fused into actively-transcribed genes, and 3-8 % into ribosomal DNA [247].”
BackgroundWang, Z., Ma, H.-I., Li, J., Sun, L., Zhang, J., & Xiao, X. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302133 · Cited by 367 · cited 1×
“mini CAG (SV40 Intron) 800 Ubiquitous, +++ [64]”
Inner limiting membrane barriers to aav-mediated retinal transduction from the vitreous
Dalkara, D., Kolstad, K. D., Caporale, N., Visel, M., Klimczak, R. R., Schaffer, D. V., & Flannery, J. G. (2009) · Molecular Therapy · doi:10.1038/mt.2009.181 · Cited by 357 · cited 12×
“However, under the disease condition or enzymatic digestion of the ILM, all rAAV (1, 2, 5, 8, and 9) traversed, most likely via Müller glial cells, to RPE cells through the retina [99,304,308].”
BackgroundInfluentialWoodchuck hepatitis virus contains a tripartite posttranscriptional regulatory element
Donello, J. E., Loeb, J. E., & Hope, T. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.6.5085-5092.1998 · Cited by 350 · cited 2×
“Woodchuck Hepatitis Virus PRE (WPRE) 600 +++, 6-10x increase [139,150]”
BackgroundTan, E., Ding, X.-Q., Saadi, A., Agarwal, N., Naash, M. I., & Al-Ubaidi, M. R. (2004) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.03-1114 · Cited by 345 · cited 1×
“The 661W cells are light-sensitive but do not have visible outer segments [266,267].”
BackgroundA robust system for production of minicircle DNA vectors
Kay, M. A., He, C.-Y., & Chen, Z.-Y. (2010) · Nature Biotechnology · doi:10.1038/nbt.1708 · Cited by 329 · cited 1×
“Some researchers use, therefore, minicircle DNA vectors devoid of prokaryotic and antibiotic DNA sequences for their AAV production [228].”
In vitro characterization of a spontaneously immortalized human Müller cell line (MIO-M1).
Limb, G. A., Salt, T. E., Munro, P., Moss, S. E., & Khaw, P. T. (2002) · PubMed · Cited by 319
Capowski, E. E., Samimi, K., Mayerl, S. J., Phillips, M. J., Pinilla, I., Howden, S. E., Saha, J., Jansen, A. D., Edwards, K. L., Jager, L. D., et al. (2018) · Development · doi:10.1242/dev.171686 · Cited by 311 · cited 1×
“Another uncertainty is that the quality of the starting material (hiPSCs) and the culturing protocol can significantly affect the success in differentiation to retinal organoids inadvertently affecting rAAV tropism [289,290].”
BackgroundSamulski, R. J., Srivastava, A., Berns, K. I., & Muzyczka, N. (1983) · Cell · doi:10.1016/0092-8674(83)90342-2 · Cited by 297
Mammalian Near-Infrared Image Vision through Injectable and Self-Powered Retinal Nanoantennae
Ma, Y., Bao, J., Zhang, Y., Li, Z., Zhou, X., Wan, C., Huang, L., Zhao, Y., Han, G., & Xue, T. (2019) · Cell · doi:10.1016/j.cell.2019.01.038 · Cited by 292 · cited 1×
“However, many other potential technologies have been developed alongside, including exosomes/liposomes, antisense oligonucleotides (AONs), electroporation of naked DNA/RNA, or application of nanoparticles [12,13].”
BackgroundLeaver, S. G., Cui, Q., Plant, G. W., Arulpragasam, A., Hisheh, S., Verhaagen, J., & Harvey, A. R. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302791 · Cited by 271
Nrl knockdown by AAV-delivered CRISPR/Cas9 prevents retinal degeneration in mice
Yu, W., Mookherjee, S., Chaitankar, V., Hiriyanna, S., Kim, J.-W., Brooks, M., Ataeijannati, Y., Sun, X., Dong, L., Li, T., et al. (2017) · Nature Communications · doi:10.1038/ncomms14716 · Cited by 271 · cited 1×
“gRNA-Nrl) rescued vision in three mouse lines of rod retinal degeneration (Crx-Nrl-/-; rd10 or Pde6b-/-; Rho-/-) by knocking out Nrl in one or both alleles [219].”
BackgroundT7 Vectors with a Modified T7lacPromoter for Expression of Proteins inEscherichia coli
Peränen, J., Rikkonen, M., Hyvönen, M., & Kääriäinen, L. (1996) · Analytical Biochemistry · doi:10.1006/abio.1996.0187 · Cited by 270
Lawrence, J. M., Singhal, S., Bhatia, B., Keegan, D. J., Reh, T. A., Luthert, P. J., Khaw, P. T., & Limb, G. A. (2007) · Stem Cells · doi:10.1634/stemcells.2006-0724 · Cited by 269 · cited 1×
“However, the Müller glial-like cell line also contains mRNA for the following opsins or visual cycle-related genes: OPN1SW, OPN2, OPN3, OPN4, OPN5, RRH, GNAZ, GNAT1, and GNAT2 [275,276].”
BackgroundBennicelli, J., Wright, J. F., Komaromy, A., Jacobs, J. B., Hauck, B., Zelenaia, O., Mingozzi, F., Hui, D., Chung, D., Rex, T. S., et al. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300389 · Cited by 267
Adeno-associated virus vectors integrate at chromosome breakage sites
Miller, D. G., Petek, L. M., & Russell, D. W. (2004) · Nature Genetics · doi:10.1038/ng1380 · Cited by 266 · cited 1×
“Integration events can be increased by increasing dsDNA breaks in vitro by adding intron-encoded endonuclease I-SceI, etoposide, or γ-irradiation [244].”
BackgroundCloning of infectious adeno-associated virus genomes in bacterial plasmids
Laughlin, C. A., Tratschin, J.-D., Coon, H., & Carter, B. J. (1983) · Gene · doi:10.1016/0378-1119(83)90217-2 · Cited by 266 · cited 1×
“The generation of the first recombinant AAV (rAAV2) was already described by the labs of Nick Muzyczka and Barrie Carter in 1982–1983 [37,38].”
BackgroundA comprehensive review of retinal gene therapy
Boye, S. E., Boye, S. L., Lewin, A. S., & Hauswirth, W. W. (2013) · Molecular Therapy · doi:10.1038/mt.2012.280 · Cited by 262 · cited 2×
“Many adult mouse rAAV potency studies have been performed and are reviewed elsewhere [2,7].”
BackgroundGenetic Fate of Recombinant Adeno-Associated Virus Vector Genomes in Muscle
Schnepp, B. C., Clark, K. R., Klemanski, D. L., Pacak, C. A., & Johnson, P. R. (2003) · Journal of Virology · doi:10.1128/jvi.77.6.3495-3504.2003 · Cited by 262 · cited 1×
“(2) rAAV DNA carrier systems allow long-term treatment for at least ten years in dogs [22], (3) and primarily deliver their gene cassette in episomal concatemers into the nucleus [23].”
BackgroundBeltran, W. A., Cideciyan, A. V., Lewin, A. S., Iwabe, S., Khanna, H., Sumaroka, A., Chiodo, V. A., Fajardo, D. S., Román, A. J., Deng, W.-T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1118847109 · Cited by 260
Inherited Retinal Degenerations: Current Landscape and Knowledge Gaps
Duncan, J. L., Pierce, E. A., Laster, A. M., Daiger, S. P., Birch, D. G., Ash, J. D., Iannaccone, A., Flannery, J. G., Sahel, J. A., Zack, D. J., et al. (2018) · Translational Vision Science & Technology · doi:10.1167/tvst.7.4.6 · Cited by 257 · cited 1×
“Novel medical therapies, such as gene therapies, need to be carefully optimized to demonstrate their efficacy and safety before going into clinical human trials [10].”
BackgroundCpG-depleted adeno-associated virus vectors evade immune detection
Faust, S. M., Bell, P., Cutler, B. J., Ashley, S. N., Zhu, Y., Rabinowitz, J. E., & Wilson, J. M. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68205 · Cited by 254 · cited 1×
“Recent studies indicated that the reduction of CpG islands in rAAV vectors increased transgene expression and reduced TLR9-mediated innate immune detection [46,47].”
BackgroundA microRNA-regulated lentiviral vector mediates stable correction of hemophilia B mice
Brown, B. D., Cantore, A., Annoni, A., Sergi, L. S., Lombardo, A., Della Valle, P., D'Angelo, A., & Naldini, L. (2007) · Blood · doi:10.1182/blood-2007-03-078493 · Cited by 252 · cited 1×
“presenting cells (APCs) with miR-142-3p [146].”
Ellis, B. L., Hirsch, M. L., Barker, J. C., Connelly, J. P., Steininger, R. J., & Porteus, M. H. (2013) · Virology Journal · doi:10.1186/1743-422x-10-74 · Cited by 252
Klein, R. L., Meyer, E. M., Peel, A. L., Zolotukhin, S., Meyers, C., Muzyczka, N., & King, M. A. (1998) · Experimental Neurology · doi:10.1006/exnr.1997.6736 · Cited by 251
van de Pavert, S. A., Kantardzhieva, A., Malysheva, A., Meuleman, J., Versteeg, I., Levelt, C., Klooster, J., Geiger, S., Seeliger, M. W., Rashbass, P., et al. (2004) · Journal of Cell Science · doi:10.1242/jcs.01301 · Cited by 250
Self-citationAAV cis -regulatory sequences are correlated with ocular toxicity
Xiong, W., Wu, D. M., Xue, Y., Wang, S. K., Chung, M. J., Ji, X., Rana, P., Zhao, S. R., Mai, S., & Cepko, C. L. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1821000116 · Cited by 249 · cited 3×
“The ubiquitous UbC promoter showed no toxicity to the mouse RPE [324].”
BackgroundInfluentialNovel adeno-associated virus serotypes efficiently transduce murine photoreceptors
Allocca, M., Mussolino, C., Garcia-Hoyos, M., Sanges, D., Iodice, C., Petrillo, M., Vandenberghe, L. H., Wilson, J. M., Marigo, V., Surace, E. M., et al. (2007) · Journal of Virology · doi:10.1128/jvi.01327-07 · Cited by 246 · cited 1×
“Mouse RHO 1400 Rod PRCs [104] Human RHO (rhodopsin) 800 Rod PRCs [105] Human RHO 520 Rod- PRCs [24]”
BackgroundHumoral immune response to AAV
Calcedo, R., & Wilson, J. M. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00341 · Cited by 243 · cited 1×
“The immune reactions range from induction of neutralizing antibodies that reduce the number of capsids reaching the target cells to the innate immune pathways silencing the gene cassette within the host cell, as well as the cell-mediated T-cell immune response against foreign protein expression [27].”
BackgroundLight and the laboratory mouse
Peirson, S. N., Brown, L. A., Pothecary, C. A., Benson, L. A., & Fisk, A. S. (2018) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2017.04.007 · Cited by 234 · cited 1×
“This CD-1 mouse line is prone to hearing and vision loss, whereas albino mice are more susceptible to light-induced retinal damage [325].”
BackgroundSalva, M. Z., Himeda, C. L., Tai, P. W., Nishiuchi, E., Gregorevic, P., Allen, J. M., Finn, E. E., Nguyen, Q. G., Blankinship, M. J., Meuse, L., et al. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300027 · Cited by 232
Heier, J. S., Kherani, S., Desai, S., Dugel, P., Kaushal, S., Cheng, S. H., Delacono, C., Purvis, A., Richards, S., Le-Halpere, A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30979-0 · Cited by 229
Jüttner, J., Szabo, A., Gross-Scherf, B., Morikawa, R. K., Rompani, S. B., Hantz, P., Szikra, T., Esposti, F., Cowan, C. S., Bharioke, A., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-019-0431-2 · Cited by 218
Lentiviral vectors for enhanced gene expression in human hematopoietic cells
Ramezani, A., Hawley, T. S., & Hawley, R. G. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0190 · Cited by 217 · cited 16×
“WPRE.4xmiRNA204T significantly reduced eGFP expression in RPE cells after subretinal injection in mice and pigs.”
BackgroundInfluentialKong, J., Kim, S.-R., Binley, K., Pata, I., Doi, K., Mannik, J., Zernant-Rajang, J., Kan, O., Iqball, S., Naylor, S., et al. (2008) · Gene Therapy · doi:10.1038/gt.2008.78 · Cited by 215
Gill, D., Smyth, S., Goddard, C., Pringle, I., Higgins, C., Colledge, W., & Hyde, S. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301561 · Cited by 214 · cited 1×
“(TATA box, Inr, MTE and DPE) [48] EF1-α 2500 Ubiquitous, ++ [51,70] PGK 426 Ubiquitous, ++ [53] UbC 403 Ubiquitous, ++ [70]”
Pharmaceutical development of AAV-based gene therapy products for the eye
Rodrigues, G. A., Shalaev, E., Karami, T. K., Cunningham, J., Slater, N. K. H., & Rivers, H. M. (2019) · Pharmaceutical Research · doi:10.1007/s11095-018-2554-7 · Cited by 213
Intravitreal injection of AAV2 transduces macaque inner retina
Yin, L., Greenberg, K., Hunter, J. J., Dalkara, D., Kolstad, K. D., Masella, B. D., Wolfe, R., Visel, M., Stone, D., Libby, R. T., et al. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-6250 · Cited by 212 · cited 1×
“Intravitreal injection (ubiquitous promoter): rAAV2 infects Müller glial cells and ganglion cells [322].”
BackgroundKlimczak, R. R., Koerber, J. T., Dalkara, D., Flannery, J. G., & Schaffer, D. V. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007467 · Cited by 210 · cited 1×
“An example are the rAAV6 variants ShH10 and ShH10-Y445F that efficiently infect rat, mouse, and human Müller glial cells [60,62,272].”
BackgroundAkl, M. R., Nagpal, P., Ayoub, N. M., Tai, B., Prabhu, S. A., Capac, C. M., Gliksman, M., Goy, A., & Suh, K. S. (2016) · Oncotarget · doi:10.18632/oncotarget.8203 · Cited by 209 · cited 4×
“Other rAAV serotypes, such as AAV4, are less dependent on the HSPGs and FGFRs for rAAV capsid cell entry [285].”
BackgroundInfluentialEfficient Non-Viral Ocular Gene Transfer with Compacted DNA Nanoparticles
Farjo, R., Skaggs, J., Quiambao, A. B., Cooper, M. J., & Naash, M. I. (2006) · PLoS ONE · doi:10.1371/journal.pone.0000038 · Cited by 208 · cited 1×
“eGFP DNA incorporated into nanoparticles showed robust expression in the retina after two days, but the expression was not detectable after two weeks [59].”
Backgroundden Hollander, A. I., Black, A., Bennett, J., & Cremers, F. P. M. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42258 · Cited by 207
LaVail, M. M., Yasumura, D., Matthes, M. T., Drenser, K. A., Flannery, J. G., Lewin, A. S., & Hauswirth, W. W. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.210319397 · Cited by 203
Choi, J.-H., Yu, N.-K., Baek, G.-C., Bakes, J., Seo, D., Nam, H. J., Baek, S. H., Lim, C.-S., Lee, Y.-S., & Kaang, B.-K. (2014) · Molecular Brain · doi:10.1186/1756-6606-7-17 · Cited by 188 · cited 4×
“A shorter version of the WPRE (WPRE3; 247 bp) showed only a 15% drop in expression in hippocampal neuron cultures or GFP expression in rAAV infected hippocampal CA1 region in the mouse brain [139].”
BackgroundInfluentialBochkov, Y. A., & Palmenberg, A. C. (2006) · BioTechniques · doi:10.2144/000112243 · Cited by 188 · cited 1×
“The interspersing IRES (572 bp) or minimum IRES (436 bp) allows efficient expression of independent genes into cap-independent RNA transcripts [72].”
BackgroundBardet-Biedl Syndrome and Related Disorders
Schachat, A. P., & Maumenee, I. H. (1982) · Archives of Ophthalmology · doi:10.1001/archopht.1982.01030030287011 · Cited by 186
Michalakis, S., Mühlfriedel, R., Tanimoto, N., Krishnamoorthy, V., Koch, S., Fischer, M. D., Becirovic, E., Bai, L., Huber, G., Beck, S. C., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.149 · Cited by 185 · cited 1×
“5 ~600 Red cone PRCs [106] Mouse blue opsin (mBP500) 500 Mouse S opsin [113] Human interphotoreceptor retinoid binding protein (hIRBP) 235 Cone and rod PRCs X53044.”
BackgroundMolecular evolution of adeno-associated virus for enhanced glial gene delivery
Koerber, J. T., Klimczak, R., Jang, J.-H., Dalkara, D., Flannery, J. G., & Schaffer, D. V. (2009) · Molecular Therapy · doi:10.1038/mt.2009.184 · Cited by 181 · cited 1×
“(5) The capsid composition can be adjusted to fit one’s goals [25].”
BackgroundGil-Farina, I., Fronza, R., Kaeppel, C., Lopez-Franco, E., Ferreira, V., D'Avola, D., Benito, A., Prieto, J., Petry, H., Gonzalez-Aseguinolaza, G., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.52 · Cited by 179 · cited 1×
“Unmistakably, many successful AAV gene therapies in mice and >130 rAAV clinical trials in humans, have indirectly suggested that the genome integration / genotoxic events are of a lesser concern [249].”
BackgroundFischer, M. D., Michalakis, S., Wilhelm, B., Zobor, D., Muehlfriedel, R., Kohl, S., Weisschuh, N., Ochakovski, G. A., Klein, R., Schoen, C., et al. (2020) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2020.1032 · Cited by 177
Xu, L., Daly, T., Gao, C., Flotte, T. R., Song, S., Byrne, B. J., Sands, M. S., & Ponder, K. P. (2001) · Human Gene Therapy · doi:10.1089/104303401300042500 · Cited by 171 · cited 1×
“(TATA box, Inr, MTE and DPE) [48] EF1-α 2500 Ubiquitous, ++ [51,70] PGK 426 Ubiquitous, ++ [53] UbC 403 Ubiquitous, ++ [70]”
Zhang, Z., Ma, Z., Zou, W., Guo, H., Liu, M., Ma, Y., & Zhang, L. (2019) · BioMed Research International · doi:10.1155/2019/9605265 · Cited by 164
Retinal degeneration is slowed in transgenic rats by AAV-mediated delivery of FGF-2.
Lau, D., McGee, L. H., Zhou, S., Rendahl, K. G., Manning, W. C., Escobedo, J. A., & Flannery, J. G. (2000) · PubMed · Cited by 163
Mellough, C. B., Sernagor, E., Moreno-Gimeno, I., Steel, D. H. W., & Lako, M. (2012) · Stem Cells · doi:10.1002/stem.1037 · Cited by 162
Gene therapy progress and prospects: the eye
Bainbridge, J. W., Tan, M. H., & Ali, R. R. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302812 · Cited by 162
A Review of Anti-Angiogenic Targets for Monoclonal Antibody Cancer Therapy
Kong, D.-H., Kim, M., Jang, J., Na, H.-J., & Lee, S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081786 · Cited by 161
Choroideremia gene therapy phase 2 clinical trial: 24-month results
Lam, B. L., Davis, J. L., Gregori, N. Z., MacLaren, R. E., Girach, A., Verriotto, J. D., Rodriguez, B., Rosa, P. R., Zhang, X., & Feuer, W. J. (2019) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2018.09.012 · Cited by 161
Rumachik, N. G., Malaker, S. A., Poweleit, N., Maynard, L. H., Adams, C. M., Leib, R. D., Cirolia, G., Thomas, D., Stamnes, S., Holt, K., et al. (2019) · doi:10.1101/640169 · Cited by 156
Tailoring the AAV vector capsid for gene therapy
Vandenberghe, L. H., Wilson, J. M., & Gao, G. (2009) · Gene Therapy · doi:10.1038/gt.2008.170 · Cited by 155
Rumachik, N. G., Malaker, S. A., Poweleit, N., Maynard, L. H., Adams, C. M., Leib, R. D., Cirolia, G., Thomas, D., Stamnes, S., Holt, K., et al. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.05.018 · Cited by 154 · cited 2×
“A preliminary study investigated if the choice of the production cell line might influence the tropism and potency of the rAAV vector [44].”
BackgroundWu, Z., Sun, J., Zhang, T., Yin, C., Yin, F., Van Dyke, T., Samulski, R. J., & Monahan, P. E. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300355 · Cited by 153 · cited 4×
“Especially, the strong MVM intron-1 of the viral capsid protein (VP-1) of only 67-to-97 bp can increase the transcript expression by 10x [143].”
BackgroundInfluentialTomita, H., Sugano, E., Isago, H., Hiroi, T., Wang, Z., Ohta, E., & Tamai, M. (2010) · Experimental Eye Research · doi:10.1016/j.exer.2009.12.006 · Cited by 148
Evaluation of Dose and Safety of AAV7m8 and AAV8BP2 in the Non-Human Primate Retina
Ramachandran, P. S., Lee, V., Wei, Z., Song, J. Y., Casal, G., Cronin, T., Willett, K., Huckfeldt, R., Morgan, J. I. W., Aleman, T. S., et al. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.111 · Cited by 147 · cited 2×
“rAAV8BP2, rAAV9 and rAAV5 infect cone photoreceptors more efficiently than rAAV2 [318,319,321].”
BackgroundNext-generation AAV vectors—Do not judge a virus (only) by its cover
Domenger, C., & Grimm, D. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz148 · Cited by 147 · cited 2×
“A recent review reported a rAAV-CRISPR vector that can self-inactivate its Cas9 protein by encoding an anti-Cas9 gRNA on the same construct that harbors the Cas9 itself [148].”
BackgroundThe University of North Carolina at Chapel Hill University Libraries (2015) · The University of North Carolina at Chapel Hill University Libraries · doi:10.17615/2x9m-k248 · Cited by 145
Khani, S. C., Pawlyk, B. S., Bulgakov, O. V., Kasperek, E., Young, J. E., Adamian, M., Sun, X., Smith, A. J., Ali, R. R., & Li, T. (2007) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.07-0257 · Cited by 139
Long-term outcomes of gene therapy for the treatment of Leber’s hereditary optic neuropathy
Yang, S., Ma, S.-Q., Wan, X., He, H., Pei, H., Zhao, M.-J., Chen, C., Wang, D.-W., Dong, X.-Y., Yuan, J.-J., et al. (2016) · eBioMedicine · doi:10.1016/j.ebiom.2016.07.002 · Cited by 139 · cited 3×
“Most rAAVs were produced in HEK293(T) cells without the use of helper viruses except for the products tgAAG76 (B50 cell line and helper adenovirus; [39]), rAAV2/2-ND4 (HEK293 infected by HSV1-rc/∆UL2; [40]), rAAV2tYF-CB-hRS1/rAAV2tYF-PR1.”
BackgroundInfluentialOhlfest, J. R., Frandsen, J. L., Fritz, S., Lobitz, P. D., Perkinson, S. G., Clark, K. J., Nelsestuen, G., Key, N. S., McIvor, R. S., Hackett, P. B., et al. (2005) · Blood · doi:10.1182/blood-2004-09-3496 · Cited by 136
Introns Protect Eukaryotic Genomes from Transcription-Associated Genetic Instability
Bonnet, A., Grosso, A. R., Elkaoutari, A., Coleno, E., Presle, A., Sridhara, S. C., Janbon, G., Géli, V., de Almeida, S. F., & Palancade, B. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.07.002 · Cited by 135 · cited 1×
“Moreover, an intron can dictate the mRNA export mechanism from the nucleus to the endoplasmic reticulum [181,182].”
BackgroundStable RNA interference: Comparison of U6 and H1 promoters in endothelial cells and in mouse brain
Mäkinen, P. I., Koponen, J. K., Kärkkäinen, A., Malm, T. M., Pulkkinen, K. H., Koistinaho, J., Turunen, M. P., & Ylä‐Herttuala, S. (2006) · The Journal of Gene Medicine · doi:10.1002/jgm.860 · Cited by 134 · cited 1×
“However, the relatively large size, the requirement that the transcript starts with a G or A, the sometimes too active transcription, and the sensitivity to specific cellular profiles make the human U6 promoter a less versatile promoter [88,131,132].”
BackgroundClinical applications of retinal gene therapy
Lipinski, D. M., Thake, M., & MacLaren, R. E. (2012) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2012.09.001 · Cited by 132
Triple Vectors Expand AAV Transfer Capacity in the Retina
Maddalena, A., Tornabene, P., Tiberi, P., Minopoli, R., Manfredi, A., Mutarelli, M., Rossi, S., Simonelli, F., Naggert, J. K., Cacchiarelli, D., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.11.019 · Cited by 128 · cited 1×
“1, bp 4,870–5,516 [126,129] Synpiii 1317 + SV40 mini promoter [130]”
Dorrell, M. I., Aguilar, E., Jacobson, R., Yanes, O., Gariano, R., Heckenlively, J., Banin, E., Ramirez, G. A., Gasmi, M., Bird, A., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci35977 · Cited by 127 · cited 1×
“CHX10 164 Retinal progenitor cells [98] GFAP 2600 Müller glial cells, [99,100] GFAP 2200 Müller glial cells (Novartis) [101] GfaABC1D 686 Müller glial cells [96,97]”
BackgroundImproving Transcriptional Termination of Self-inactivating Gamma-retroviral and Lentiviral Vectors
Schambach, A., Galla, M., Maetzig, T., Loew, R., & Baum, C. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300152 · Cited by 127 · cited 1×
“Polyadenylation Size Description, Strength References SV40 late 135 +++ [139] 2x SV40 late 100 ++/+++ [169] bGHpolyA 250 ++ [149] 2x sNRP1 34 +/++ [167] Rabbit gbpA 56 Rabbit β-globin [149] spA 49 +/++ (7x lower than bGHpolyA, 3x lower than SV40 late) [139,149] hGHpolyA 624 + [41,170,171] 1x sNRP1 17 + [167]”
Grishanin, R., Vuillemenot, B., Sharma, P., Keravala, A., Greengard, J., Gelfman, C., Blumenkrantz, M., Lawrence, M., Hu, W., Kiss, S., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2018.11.003 · Cited by 127 · cited 4×
“Nonmembrane associated splice variant of VEGFR1 encoded by the FLT1 gene; Adverum Biotechnologies; Sanofi Genzyme) [41,205,206], (2) endostatin (cleavage product of collagen XVIII) / angiostatin (cleavage product of fibrinogen; Oxford Biomedica) [207], (3) the complement factor I (CFI, a C3b/C4b inactivator in the com…”
BackgroundInfluentialExpression Specificity of GFAP Transgenes
Su, M., Hu, H., Lee, Y., D’Azzo, A., Messing, A., & Brenner, M. (2004) · Neurochemical Research · doi:10.1007/s11064-004-6881-1 · Cited by 124 · cited 2×
“CHX10 164 Retinal progenitor cells [98] GFAP 2600 Müller glial cells, [99,100] GFAP 2200 Müller glial cells (Novartis) [101] GfaABC1D 686 Müller glial cells [96,97]”
BackgroundNoninvasive gene delivery to foveal cones for vision restoration
Khabou, H., Garita-Hernandez, M., Chaffiol, A., Reichman, S., Jaillard, C., Brazhnikova, E., Bertin, S., Forster, V., Desrosiers, M., Winckler, C., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.96029 · Cited by 124 · cited 2×
“rAAV2(quad Y-F) and rAAV2-7m8 also infected Müller glial cells and some rod photoreceptor cells ex vivo [293,294].”
BackgroundGlover, C. P. J., Bienemann, A. S., Heywood, D. J., Cosgrave, A. S., & Uney, J. B. (2002) · Molecular Therapy · doi:10.1006/mthe.2002.0588 · Cited by 120
Sequence requirements for binding of Rep68 to the adeno-associated virus terminal repeats
Ryan, J. H., Zolotukhin, S., & Muzyczka, N. (1996) · Journal of Virology · doi:10.1128/jvi.70.3.1542-1553.1996 · Cited by 119
Tan, M. H., Smith, A. J., Pawlyk, B., Xu, X., Liu, X., Bainbridge, J. B., Basche, M., McIntosh, J., Tran, H. V., Nathwani, A., et al. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp133 · Cited by 119
Tsai, Y.-T., Wu, W.-H., Lee, T.-T., Wu, W.-P., Xu, C. L., Park, K. S., Cui, X., Justus, S., Lin, C.-S., Jauregui, R., et al. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2018.04.001 · Cited by 119 · cited 1×
“SV40-polyA) rescuing retinal degeneration [61].”
Cashman, S. M., Ramo, K., & Kumar-Singh, R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019078 · Cited by 118 · cited 2×
“Nonmembrane associated splice variant of VEGFR1 encoded by the FLT1 gene; Adverum Biotechnologies; Sanofi Genzyme) [41,205,206], (2) endostatin (cleavage product of collagen XVIII) / angiostatin (cleavage product of fibrinogen; Oxford Biomedica) [207], (3) the complement factor I (CFI, a C3b/C4b inactivator in the com…”
BackgroundBoye, S. E., Alexander, J. J., Boye, S. L., Witherspoon, C. D., Sandefer, K. J., Conlon, T. J., Erger, K., Sun, J., Ryals, R., Chiodo, V. A., et al. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.125 · Cited by 117 · cited 2×
“The hGRK1 promoter expressed GFP specifically in rod- and cone photoreceptors [321].”
BackgroundAn Alternate Route for Adeno-associated Virus (AAV) Entry Independent of AAV Receptor
Dudek, A. M., Pillay, S., Puschnik, A. S., Nagamine, C. M., Cheng, F., Qiu, J., Carette, J. E., & Vandenberghe, L. H. (2018) · Journal of Virology · doi:10.1128/jvi.02213-17 · Cited by 117 · cited 2×
“Other rAAV serotypes, such as AAV4, are less dependent on the HSPGs and FGFRs for rAAV capsid cell entry [285].”
BackgroundAAV-Mediated Cone Rescue in a Naturally Occurring Mouse Model of CNGA3-Achromatopsia
Pang, J.-J., Deng, W.-T., Dai, X., Lei, B., Everhart, D., Umino, Y., Li, J., Zhang, K., Mao, S., Boye, S. L., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035250 · Cited by 114 · cited 1×
“Human blue opsin HB570 570 S-cone and subset of M-cones PRCs [111] Human blue opsin HB569 569 blue cone opsin PRCs [106,112] PR0.”
BackgroundKim, D. S., Matsuda, T., & Cepko, C. L. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.0397-08.2008 · Cited by 114 · cited 5×
“Bipolar cells and Müller glial cells [98] Grm6-mGluR500P 700 On-bipolar cells.”
BackgroundInfluentialOptimization of Plasmid Vectors for High-Level Expression in Lung Epithelial Cells
Yew, N. S., Wysokenski, D. M., Wang, K. X., Ziegler, R. J., Marshall, J., McNeilly, D., Cherry, M., Osburn, W., & Cheng, S. H. (1997) · Human Gene Therapy · doi:10.1089/hum.1997.8.5-575 · Cited by 113 · cited 4×
“5-67x increase; -118/-522 TSS pCMVβ / 5′CMV enhancer [149]”
BackgroundInfluentialDalkara, D., Kolstad, K. D., Guerin, K. I., Hoffmann, N. V., Visel, M., Klimczak, R. R., Schaffer, D. V., & Flannery, J. G. (2011) · Molecular Therapy · doi:10.1038/mt.2011.62 · Cited by 110
Lotery, A. J., Yang, G. S., Mullins, R. F., Russell, S. R., Schmidt, M., Stone, E. M., Lindbloom, J. D., Chiorini, J. A., Kotin, R. M., & Davidson, B. L. (2003) · Human Gene Therapy · doi:10.1089/104303403322542301 · Cited by 107
Gene Therapy in Retinal Dystrophies
Ziccardi, L., Cordeddu, V., Gaddini, L., Matteucci, A., Parravano, M., Malchiodi-Albedi, F., & Varano, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225722 · Cited by 107 · cited 1×
“In most clinical retinal gene therapy studies, the vector of choice is the rAAV gene expression vector [14].”
BackgroundOstedgaard, L. S., Rokhlina, T., Karp, P. H., Lashmit, P., Afione, S., Schmidt, M., Zabner, J., Stinski, M. F., Chiorini, J. A., & Welsh, M. J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409845102 · Cited by 105 · cited 1×
“Polyadenylation Size Description, Strength References SV40 late 135 +++ [139] 2x SV40 late 100 ++/+++ [169] bGHpolyA 250 ++ [149] 2x sNRP1 34 +/++ [167] Rabbit gbpA 56 Rabbit β-globin [149] spA 49 +/++ (7x lower than bGHpolyA, 3x lower than SV40 late) [139,149] hGHpolyA 624 + [41,170,171] 1x sNRP1 17 + [167]”
Wang, X. S., Ponnazhagan, S., & Srivastava, A. (1996) · Journal of Virology · doi:10.1128/jvi.70.3.1668-1677.1996 · Cited by 104 · cited 1×
“rAAV can be produced with only one ITR if the other ITR shows specific deletions, and ITR deletions can be recovered during production [233,236].”
BackgroundPechan, P., Rubin, H., Lukason, M., Ardinger, J., DuFresne, E., Hauswirth, W. W., Wadsworth, S. C., & Scaria, A. (2009) · Gene Therapy · doi:10.1038/gt.2008.115 · Cited by 104 · cited 2×
“Nonmembrane associated splice variant of VEGFR1 encoded by the FLT1 gene; Adverum Biotechnologies; Sanofi Genzyme) [41,205,206], (2) endostatin (cleavage product of collagen XVIII) / angiostatin (cleavage product of fibrinogen; Oxford Biomedica) [207], (3) the complement factor I (CFI, a C3b/C4b inactivator in the com…”
Backgroundvan Rossum, A. G. S. H., Aartsen, W. M., Meuleman, J., Klooster, J., Malysheva, A., Versteeg, I., Arsanto, J.-P., Le Bivic, A., & Wijnholds, J. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl194 · Cited by 104 · cited 1×
“We have previously shown that mouse retinal explants at P0 can be cultured longer than adult retinal explants [189].”
BackgroundSelf-citationEggermont, J., & Proudfoot, N. J. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05909.x · Cited by 103
Zallocchi, M., Binley, K., Lad, Y., Ellis, S., Widdowson, P., Iqball, S., Scripps, V., Kelleher, M., Loader, J., Miskin, J., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094272 · Cited by 102
Short DNA Hairpins Compromise Recombinant Adeno-Associated Virus Genome Homogeneity
Xie, J., Mao, Q., Tai, P. W. L., He, R., Ai, J., Su, Q., Zhu, Y., Ma, H., Li, J., Gong, S., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.028 · Cited by 102 · cited 3×
“Moreover, replacing the 5′ ITR with a U-shaped hairpin allows rAAV production and episomal concatemerization [147].”
BackgroundInfluentialProspects for retinal gene replacement therapy
Smith, A. J., Bainbridge, J. W., & Ali, R. R. (2009) · Trends in Genetics · doi:10.1016/j.tig.2009.02.003 · Cited by 99
Takahashi, K., Igarashi, T., Miyake, K., Kobayashi, M., Yaguchi, C., Iijima, O., Yamazaki, Y., Katakai, Y., Miyake, N., Kameya, S., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.10.008 · Cited by 99 · cited 1×
“Self-complementary rAAV2tYFinfects Müller glial cells, at least if the ILM is peeled off before injection [323].”
BackgroundAAV9 targets cone photoreceptors in the nonhuman primate retina
Vandenberghe, L. H., Bell, P., Maguire, A. M., Xiao, R., Hopkins, T. B., Grant, R., Bennett, J., & Wilson, J. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053463 · Cited by 97 · cited 1×
“rAAV8BP2, rAAV9 and rAAV5 infect cone photoreceptors more efficiently than rAAV2 [318,319,321].”
BackgroundQuinn, P. M., Buck, T. M., Mulder, A. A., Ohonin, C., Alves, C. H., Vos, R. M., Bialecka, M., van Herwaarden, T., van Dijk, E. H. C., Talib, M., et al. (2019) · Stem Cell Reports · doi:10.1016/j.stemcr.2019.03.002 · Cited by 97 · cited 2×
“Similarly, the expression of GFP was detected after two to four weeks in human iPSC-derived retinal organoids transduced with rAAV-CMV-eGFP vectors [62].”
BackgroundSelf-citationNon-immunogenic utrophin gene therapy for the treatment of muscular dystrophy animal models
Song, Y., Morales, L., Malik, A. S., Mead, A. F., Greer, C. D., Mitchell, M. A., Petrov, M. T., Su, L. T., Choi, M. E., Rosenblum, S. T., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0594-0 · Cited by 97 · cited 1×
“Instead of employing a shortened protein, one can also apply a surrogate protein such as utrophin for dystrophin [185,188].”
BackgroundSayyad, Z., Sirohi, K., Radha, V., & Swarup, G. (2017) · Scientific Reports · doi:10.1038/s41598-017-17241-0 · Cited by 96 · cited 1×
“The 661W cells are light-sensitive but do not have visible outer segments [266,267].”
BackgroundGenotypic and Phenotypic Characteristics of CRB1 -Associated Retinal Dystrophies
Talib, M., van Schooneveld, M. J., van Genderen, M. M., Wijnholds, J., Florijn, R. J., ten Brink, J. B., Schalij-Delfos, N. E., Dagnelie, G., Cremers, F. P. M., Wolterbeek, R., et al. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2017.01.047 · Cited by 95
Self-citationTrapani, I., Toriello, E., de Simone, S., Colella, P., Iodice, C., Polishchuk, E. V., Sommella, A., Colecchi, L., Rossi, S., Simonelli, F., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv386 · Cited by 94 · cited 1×
“An update on dual and triple rAAV vectors can be found in a recent paper by Trapani [214] who successfully applied a dual ABCA4 AAV vector system in Abca4 knockout mice [215,216].”
BackgroundDosage thresholds and influence of transgene cassette in adeno-associated virus–related toxicity
Khabou, H., Cordeau, C., Pacot, L., Fisson, S., & Dalkara, D. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.144 · Cited by 93
An AAV Dual Vector Strategy Ameliorates the Stargardt Phenotype in Adult Abca4 −/− Mice
McClements, M. E., Barnard, A. R., Singh, M. S., Charbel Issa, P., Jiang, Z., Radu, R. A., & MacLaren, R. E. (2019) · Human Gene Therapy · doi:10.1089/hum.2018.156 · Cited by 92 · cited 1×
“An update on dual and triple rAAV vectors can be found in a recent paper by Trapani [214] who successfully applied a dual ABCA4 AAV vector system in Abca4 knockout mice [215,216].”
BackgroundXu, L., Zhao, L., Gao, Y., Xu, J., & Han, R. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw1048 · Cited by 91
CD44 expression and regulation during mammary gland development and function
Hebbard, L., Steffen, A., Zawadzki, V., et al. (2000) · Journal of Cell Science · doi:10.1242/jcs.113.14.2619 · Cited by 90
Blasiak, J., Piechota, M., Pawlowska, E., Szatkowska, M., Sikora, E., & Kaarniranta, K. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/5293258 · Cited by 90
Katoh, Y., Michisaka, S., Nozaki, S., Funabashi, T., Hirano, T., Takei, R., & Nakayama, K. (2017) · Molecular Biology of the Cell · doi:10.1091/mbc.e17-01-0051 · Cited by 88
Antibiotic-free selection in biotherapeutics: Now and forever
Mignon, C., Sodoyer, R., & Werle, B. (2015) · Pathogens · doi:10.3390/pathogens4020157 · Cited by 87
Provost, N., Le Meur, G., Weber, M., Mendes-Madeira, A., Podevin, G., Cherel, Y., Colle, M.-A., Deschamps, J.-Y., Moullier, P., & Rolling, F. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2004.09.022 · Cited by 87 · cited 1×
“It is also interesting to point out that part of the infectious rAAV viral particles may redistribute to neighboring cells and may remain long term in the cytoplasm and nucleus [243].”
BackgroundCenik, C., Chua, H. N., Zhang, H., Tarnawsky, S. P., Akef, A., Derti, A., Tasan, M., Moore, M. J., Palazzo, A. F., & Roth, F. P. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1001366 · Cited by 87 · cited 1×
“Moreover, an intron can dictate the mRNA export mechanism from the nucleus to the endoplasmic reticulum [181,182].”
BackgroundPellissier, L. P., Quinn, P. M., Alves, C. H., Vos, R. M., Klooster, J., Flannery, J. G., Heimel, J. A., & Wijnholds, J. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv062 · Cited by 86 · cited 1×
“We have found protein expression (GFP, CRB1, or CRB2) in photoreceptors after one to three months of rAAV vector administration in wild-type and CRB1-related retinitis pigmentosa mouse models [24,60].”
BackgroundSelf-citationMiyazaki, M., Ikeda, Y., Yonemitsu, Y., Goto, Y., Sakamoto, T., Tabata, T., Ueda, Y., Hasegawa, M., Tobimatsu, S., Ishibashi, T., et al. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302028 · Cited by 85
Mellough, C. B., Collin, J., Queen, R., Hilgen, G., Dorgau, B., Zerti, D., Felemban, M., White, K., Sernagor, E., & Lako, M. (2019) · Stem Cells Translational Medicine · doi:10.1002/sctm.18-0267 · Cited by 85 · cited 1×
“Another uncertainty is that the quality of the starting material (hiPSCs) and the culturing protocol can significantly affect the success in differentiation to retinal organoids inadvertently affecting rAAV tropism [289,290].”
BackgroundGeorgiadis, A., Duran, Y., Ribeiro, J., Abelleira-Hervas, L., Robbie, S. J., Sünkel-Laing, B., Fourali, S., Gonzalez-Cordero, A., Cristante, E., Michaelides, M., et al. (2016) · Gene Therapy · doi:10.1038/gt.2016.66 · Cited by 84 · cited 3×
“Currently, the two products, rAAV2/5-NA65p-OPTIRPE65 and rAAV2/2-CAG-hRPE65v2 seemed to be at least as efficient in RPE65-deficient mouse retinal pigment epithelium [36].”
BackgroundInfluentialLecomte, E., Tournaire, B., Cogné, B., Dupont, J.-B., Lindenbaum, P., Martin-Fontaine, M., Broucque, F., Robin, C., Hebben, M., Merten, O.-W., et al. (2015) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2015.32 · Cited by 83
Role of Intron I in Expression of the Human Factor IX Gene
Kurachi, S., Hitomi, Y., Furukawa, M., & Kurachi, K. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.10.5276 · Cited by 82 · cited 1×
“IX truncated intron1 300 +, human factor IX (100x) [143,158]”
BackgroundOptimization of Retinal Gene Therapy for X-Linked Retinitis Pigmentosa Due to RPGR Mutations
Beltran, W. A., Cideciyan, A. V., Boye, S. E., Ye, G.-J., Iwabe, S., Dufour, V. L., Marinho, L. F., Swider, M., Kosyk, M. S., Sha, J., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.05.004 · Cited by 82 · cited 1×
“Such adaptations in the AGTC-501 vector resulted in reduced frequency of alternative splicing and increased mRNA stability [43,110].”
BackgroundAAV-Mediated Gene Delivery to 3D Retinal Organoids Derived from Human Induced Pluripotent Stem Cells
Garita-Hernandez, M., Routet, F., Guibbal, L., Khabou, H., Toualbi, L., Riancho, L., Reichman, S., Duebel, J., Sahel, J.-A., Goureau, O., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030994 · Cited by 82 · cited 16×
“For example, rAAV6 and rAAV-derived vectors (ShH10; ShH10-Y445F) infected hiPSCs and hiPSC-derived RPE cells properly and thoroughly [21,62,265]. rAAV2-7m8 and rAAV5 also efficiently infected RPE cells [265,284].”
BackgroundInfluentialGene therapy for retinal disease
McClements, M. E., & MacLaren, R. E. (2013) · Translational Research · doi:10.1016/j.trsl.2012.12.007 · Cited by 80 · cited 2×
“Many adult mouse rAAV potency studies have been performed and are reviewed elsewhere [2,7].”
BackgroundLoss of CRB2 in the mouse retina mimics human retinitis pigmentosa due to mutations in the CRB1 gene
Alves, C. H., Sanz Sanz, A., Park, B., Pellissier, L. P., Tanimoto, N., Beck, S. C., Huber, G., Murtaza, M., Richard, F., Sridevi Gurubaran, I., et al. (2013) · Human Molecular Genetics · doi:10.1093/hmg/dds398 · Cited by 80
Self-citationMolecular Therapies for Inherited Retinal Diseases—Current Standing, Opportunities and Challenges
Vázquez-Domínguez, I., Garanto, A., & Collin, R. W. J. (2019) · Genes · doi:10.3390/genes10090654 · Cited by 80 · cited 3×
“The company Ophthotech (now Iveric) explores the miniCEP290580–1180, a miniABCA4 (no published information available), and miniUSH2A (no published information available) for rAAV vector therapy.”
BackgroundInfluentialMECP2 Isoform-Specific Vectors with Regulated Expression for Rett Syndrome Gene Therapy
Rastegar, M., Hotta, A., Pasceri, P., Makarem, M., Cheung, A. Y. L., Elliott, S., Park, K. J., Adachi, M., Jones, F. S., Clarke, I. D., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006810 · Cited by 79 · cited 1×
“MVM Ubiquitous, ++ [54,67] MeCP2 229 ubiquitous [68] CMV 800 Ubiquitous, ++, prone to silencing [54] shCMV 220 Ubiquitous, ++ [24]”
Kumar, N., Stanford, W., de Solis, C., Aradhana, Abraham, N. D., Dao, T.-M. J., Thaseen, S., Sairavi, A., Gonzalez, C. U., & Ploski, J. E. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00413 · Cited by 79 · cited 1×
“Many Cas protein homologs and orthologs have been described with the most significant ones for rAAV gene-editing cassettes being Cas9, Cas12a (Cpf1), Cpfl1, SpCas9, SaCas9 [217].”
BackgroundSingh, H. P., Wang, S., Stachelek, K., Lee, S., Reid, M. W., Thornton, M. E., Craft, C. M., Grubbs, B. H., & Cobrinik, D. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1808903115 · Cited by 78 · cited 2×
“More astonishingly, fetal retinal tissue that maintained some photoreceptor morphology has been cultured for 293 days in vitro [298].”
Backgroundvan de Pavert, S. A., Meuleman, J., Malysheva, A., Aartsen, W. M., Versteeg, I., Tonagel, F., Kamphuis, W., McCabe, C. J., Seeliger, M. W., & Wijnholds, J. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.3496-06.2007 · Cited by 77
Self-citationLovric, J., Mano, M., Zentilin, L., Eulalio, A., Zacchigna, S., & Giacca, M. (2012) · Molecular Therapy · doi:10.1038/mt.2012.144 · Cited by 77 · cited 1×
“Non-dividing terminally differentiated cells allow efficient expression from rAAV gene therapy vectors because the cells downregulate proteins of the DNA damage response [312].”
BackgroundGonzalez-Cordero, A., Goh, D., Kruczek, K., Naeem, A., Fernando, M., kleine Holthaus, S.-M., Takaaki, M., Blackford, S. J. I., Kloc, M., Agundez, L., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.027 · Cited by 77
Timmers, A. M., Newmark, J. A., Turunen, H. T., Farivar, T., Liu, J., Song, C., Ye, G.-J., Pennock, S., Gaskin, C., Knop, D. R., et al. (2020) · Human Gene Therapy · doi:10.1089/hum.2019.144 · Cited by 77
A Composite CMV-IE Enhancer/β-Actin Promoter Is Ubiquitously Expressed in Mouse Cutaneous Epithelium
Sawicki, J. A., Morris, R. J., Monks, B. R., Sakai, K., & Miyazaki, J. (1998) · Experimental Cell Research · doi:10.1006/excr.1998.4175 · Cited by 76
Crb1 is a determinant of retinal apical Müller glia cell features
van de Pavert, S. A., Sanz, A. S., Aartsen, W. M., Vos, R. M., Versteeg, I., Beck, S. C., Klooster, J., Seeliger, M. W., & Wijnholds, J. (2007) · Glia · doi:10.1002/glia.20561 · Cited by 75
Self-citationAchberger, K., Haderspeck, J. C., Kleger, A., & Liebau, S. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.05.005 · Cited by 75 · cited 1×
“For example, human iPSC-derived retinal organoids and RPE-sheets can be cultured in a microfluidic chip system that enhances photoreceptor maturation and stabilization in vitro [291].”
BackgroundMoreno, M. L., Mérida, S., Bosch‐Morell, F., Miranda, M., & Villar, V. M. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.01008 · Cited by 75
Targeted Ablation of Crb1 and Crb2 in Retinal Progenitor Cells Mimics Leber Congenital Amaurosis
Pellissier, L. P., Alves, C. H., Quinn, P. M., Vos, R. M., Tanimoto, N., Lundvig, D. M. S., Dudok, J. J., Hooibrink, B., Richard, F., Beck, S. C., et al. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003976 · Cited by 73
Self-citationAdeno-Associated Viral Vectors as a Tool for Large Gene Delivery to the Retina
Trapani, I. (2019) · Genes · doi:10.3390/genes10040287 · Cited by 73 · cited 2×
“An update on dual and triple rAAV vectors can be found in a recent paper by Trapani [214] who successfully applied a dual ABCA4 AAV vector system in Abca4 knockout mice [215,216].”
BackgroundCereso, N., Pequignot, M. O., Robert, L., Becker, F., De Luca, V., Nabholz, N., Rigau, V., De Vos, J., Hamel, C. P., & Kalatzis, V. (2014) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2014.11 · Cited by 72 · cited 1×
“rAAV-REP1 vector transduction of patient hiPSC-derived CHM-RPE rescued the biochemical phenotype [279].”
BackgroundHickey, D. G., Edwards, T. L., Barnard, A. R., Singh, M. S., de Silva, S. R., McClements, M. E., Flannery, J. G., Hankins, M. W., & MacLaren, R. E. (2017) · Gene Therapy · doi:10.1038/gt.2017.85 · Cited by 72 · cited 4×
“Enzymatic digestion (proteasome inhibitors) of the ILM or ILM/outer limiting membrane (OLM) or disruptions of the ILM/OLM by the disease can alter rAAV infection and allow rAAV infection deeper into the retina [99,294,304,305].”
BackgroundInfluentialCharacterization of infectious molecular clones of equine infectious anaemia virus
Payne, S. L., Rausch, J., Rushlow, K., Montelaro, R. C., Issel, C., Flaherty, M., Perry, S., Sellon, D., & Fuller, F. (1994) · Journal of General Virology · doi:10.1099/0022-1317-75-2-425 · Cited by 70
Lu, Q., Ganjawala, T. H., Ivanova, E., Cheng, J. G., Troilo, D., & Pan, Z.-H. (2016) · Gene Therapy · doi:10.1038/gt.2016.42 · Cited by 70 · cited 1×
“[124] In4s-In3e- Grm6-mGluR500P 1997 690 bp shortened Intron 4s + 807 bp Intron 3 + 500 bp mGluR500P [124]”
Ronzitti, G., Bortolussi, G., van Dijk, R., Collaud, F., Charles, S., Leborgne, C., Vidal, P., Martin, S., Gjata, B., Sola, M. S., et al. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.49 · Cited by 69 · cited 1×
“Different codon optimizations have been tested for the rAAV gene therapy for Crigler-Najjar syndrome that increased the FIX transgene expression by 4-10-fold [253], and codon-optimization of rAAV2/5.”
MethodAssessment of Adeno-Associated Virus Serotype Tropism in Human Retinal Explants
Wiley, L. A., Burnight, E. R., Kaalberg, E. E., Jiao, C., Riker, M. J., Halder, J. A., Luse, M. A., Han, I. C., Russell, S. R., Sohn, E. H., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.179 · Cited by 68
Long-term Structural Outcomes of Late-stage RPE65 Gene Therapy
Gardiner, K. L., Cideciyan, A. V., Swider, M., Dufour, V. L., Sumaroka, A., Komáromy, A. M., Hauswirth, W. W., Iwabe, S., Jacobson, S. G., Beltran, W. A., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.08.013 · Cited by 67 · cited 2×
“ten years in dogs [22], (3) and primarily deliver their gene cassette in episomal concatemers into the”
BackgroundTargeting gene expression to cones with human cone opsin promoters in recombinant AAV
Komáromy, A. M., Alexander, J. J., Cooper, A. E., Chiodo, V. A., Acland, G. M., Hauswirth, W. W., & Aguirre, G. K. (2008) · Gene Therapy · doi:10.1038/gt.2008.32 · Cited by 66 · cited 3×
“5 ~600 Red cone PRCs [106] Mouse blue opsin (mBP500) 500 Mouse S opsin [113] Human interphotoreceptor retinoid binding protein (hIRBP) 235 Cone and rod PRCs X53044.”
BackgroundIsomura, H., Stinski, M. F., Kudoh, A., Daikoku, T., Shirata, N., & Tsurumi, T. (2005) · Journal of Virology · doi:10.1128/jvi.79.15.9597-9607.2005 · Cited by 66 · cited 1×
“For example, the transactional activation of the widely used CMV or early SV40 promoters is related to the binding of the ubiquitous transcription factors Sp1/Sp3 [92,93].”
MethodMPP5 Recruits MPP4 to the CRB1 Complex in Photoreceptors
Kantardzhieva, A., Gosens, I., Alexeeva, S., Punte, I. M., Versteeg, I., Krieger, E., Neefjes-Mol, C. A., den Hollander, A. I., Letteboer, S. J. F., Klooster, J., et al. (2005) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.04-1417 · Cited by 65
Self-citationKoilkonda, R., Yu, H., Talla, V., Porciatti, V., Feuer, W. J., Hauswirth, W. W., Chiodo, V., Erger, K. E., Boye, S. L., Lewin, A. S., et al. (2014) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.14-15388 · Cited by 65
Development of an inducible anti-VEGF rAAV gene therapy strategy for the treatment of wet AMD
Reid, C. A., Nettesheim, E. R., Connor, T. B., & Lipinski, D. M. (2018) · Scientific Reports · doi:10.1038/s41598-018-29726-7 · Cited by 65
Optogenetic Light Sensors in Human Retinal Organoids
Garita-Hernandez, M., Guibbal, L., Toualbi, L., Routet, F., Chaffiol, A., Winckler, C., Harinquet, M., Robert, C., Fouquet, S., Bellow, S., et al. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00789 · Cited by 65 · cited 1×
“We and other researchers use human retinal organoids to study rAAV transduction and potency [62,265,283,284].”
BackgroundYe, G.-J., Budzynski, E., Sonnentag, P., Nork, T. M., Miller, P. E., Sharma, A. K., Ver Hoeve, J. N., Smith, L. M., Arndt, T., Calcedo, R., et al. (2016) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2015.164 · Cited by 64
Suppression of Choroidal Neovascularization by AAV-Based Dual-Acting Antiangiogenic Gene Therapy
Askou, A. L., Alsing, S., Benckendorff, J. N. E., Holmgaard, A., Mikkelsen, J. G., Aagaard, L., Bek, T., & Corydon, T. J. (2019) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2019.01.012 · Cited by 64 · cited 1×
“The expression of cell survival factors, such as the basic fibroblast growth factor (bFGF; 470 bp), ciliary neurotrophic factor (CNTF; 600 bp), glial cell line-derived neurotrophic factor (GDNF; 511 bp), pigment endothelial-derived factor (PEDF; 883 bp) and brain-derived neurotrophic factor (BDNF; 750 bp) can be expre…”
BackgroundCole, C. N., & Stacy, T. P. (1985) · Molecular and Cellular Biology · doi:10.1128/mcb.5.8.2104 · Cited by 63 · cited 1×
“Generally used for NeoR and KanR genes [172]”
MethodChanges in adeno-associated virus-mediated gene delivery in retinal degeneration
Kolstad, K. D., Dalkara, D., Guerin, K., Visel, M., Hoffmann, N., Schaffer, D. V., & Flannery, J. G. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.194 · Cited by 63 · cited 1×
“However, under the disease condition or enzymatic digestion of the ILM, all rAAV (1, 2, 5, 8, and 9) traversed, most likely via Müller glial cells, to RPE cells through the retina [99,304,308].”
BackgroundCarvalho, L. S., Xiao, R., Wassmer, S. J., Langsdorf, A., Zinn, E., Pacouret, S., Shah, S., Comander, J. I., Kim, L. A., Lim, L., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.154 · Cited by 63
Genetics of Inherited Retinal Disease
Francis, P. J. (2006) · Journal of the Royal Society of Medicine · doi:10.1177/014107680609900417 · Cited by 62
Bocquet, B., Lacroux, A., Surget, M.-O., Baudoin, C., Marquette, V., Manes, G., Hebrard, M., Sénéchal, A., Delettre, C., Roux, A.-F., et al. (2013) · Ophthalmic Epidemiology · doi:10.3109/09286586.2012.737890 · Cited by 62
Zhu, J., Ming, C., Fu, X., Duan, Y., Hoang, D. A., Rutgard, J., Zhang, R., Wang, W., Hou, R., Zhang, D., et al. (2017) · Cell Research · doi:10.1038/cr.2017.57 · Cited by 62 · cited 1×
“Similar results have been reported in a second independent study [220].”
ResultWang, X. S., Qing, K., Ponnazhagan, S., & Srivastava, A. (1997) · Journal of Virology · doi:10.1128/jvi.71.4.3077-3082.1997 · Cited by 61
MicroRNA-Restricted Transgene Expression in the Retina
Karali, M., Manfredi, A., Puppo, A., Marrocco, E., Gargiulo, A., Allocca, M., Corte, M. D., Rossi, S., Giunti, M., Bacci, M. L., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022166 · Cited by 60
Ren, R., Li, Y., Liu, Z., Liu, K., & He, S. (2012) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.11-8484 · Cited by 60
Zhang, W., Li, L., Su, Q., Gao, G., & Khanna, H. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.049 · Cited by 60
Research works printed but not linked: 5
- Fahim, A.T., Daiger, S.P., and Weleber, R.G. (2017, January 19). Nonsyndromic Retinitis Pigmentosa Overview, Available online: http://www.ncbi.nlm.nih.gov/pubmed/20301590.
- Kremer, J.M.J., Keunen, J.E.E., and van Wijk, H.A.R. (2018). Gene therapy using miniUSH2A genes improves visual function in a zebrafish ush2a knock-out model. Towards gene therapy for USH2A-associated retinitis pigmentosa. ~Fishing for answers~ [Doctoral Thesis], Radboud University Nijmegen.
- 2017, The pathway from genes to gene therapy in glaucoma: A review of possibilities for using genes as glaucoma drugs, Asia-Pacific J. Ophthalmol., 6, 80
- Ceiler, J., Afzal, S., Leuchs, B., Fronza, R., Lulay, C., Büning, H., Schmidt, M., and Gil-Farina, I. (2017, January 10). Wild-Type and Recombinant AAV Integration in Human Cardiomyocytes: Focus on Mitochondrial Genome. Proceedings of the AAV Vector Biology, Available online: https://www.researchgate.net/publication/316699961_Wild-Type_and_Recombinant_AAV_Integration_in_Human_Cardiomyocytes_Focus_on_Mitochondrial_Genome.
- Couto, 2016, Poster C0048 ARVO: Potency Assay for AAV Vector Encoding Retinal Pigment Epithelial 65 Protein, Investig. Ophthalmol. Vis. Sci., 57, 1
Cited by
Adeno-associated virus as a delivery vector for gene therapy of human diseases
Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01780-w · Cited by 904
“116 Another study reported that a fragment of the mouse methyl-CpG-binding protein-2 promoter enabled robust long-term expression speci fi cally in neurons.”
BackgroundGene therapy advances: A meta-analysis of AAV usage in clinical settings
Au, H. K. E., Isalan, M., & Mielcarek, M. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.809118 · Cited by 284
“Selecting the right capsid and promoter is the first step to improve targeted cell transduction and expression (2, 15).”
BackgroundAAV vector development, back to the future
Suárez-Amarán, L., Song, L., Tretiakova, A. P., Mikhail, S., & Samulski, R. J. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.064 · Cited by 101
Nieuwenhuis, B., Laperrousaz, E., Tribble, J. R., Verhaagen, J., Fawcett, J. W., Martin, K. R. G., Williams, P. A., & Osborne, A. (2023) · Gene Therapy · doi:10.1038/s41434-022-00380-z · Cited by 88
Ocular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses
Ghoraba, H. H., Akhavanrezayat, A., Karaca, I., Yavari, N., Lajevardi, S., Hwang, J., Regenold, J., Matsumiya, W., Pham, B., Zaidi, M., et al. (2022) · Clinical Ophthalmology · doi:10.2147/opth.s364200 · Cited by 76
“The immune reactions include induction of neutralizing antibodies that reduce the number of capsids reaching the target cells, innate immune pathways silencing the gene cassette within the host cell, and cell-mediated T-cell immune responses against foreign protein expression.(18)”
Background
Metadata
- Authors
- Buck, T., & Wijnholds, J.
- Affiliations
- Leiden University Medical Center (NL)
- Netherlands Institute for Neuroscience (NL)
- Corresponding author
- Wijnholds, Jan
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-06-12
- Volume
- 21
- Issue
- 12
- Pages
- 4197
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC7352801
- OpenAlex
- W3035416273
- Cited by
- 92
- References
- 334
- Citations by year
- 2026: 10 · 2025: 17 · 2024: 17 · 2023: 15 · 2022: 16 · 2021: 15 · 2020: 2
- FWCI
- 1.71
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- KNAW Research Portal (The Royal Netherlands Academy of Arts and Sciences) (publishedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Leiden Repository (Leiden University) (submittedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- KNAW research portal (Royal Academy of Art and Sciences (KNAW)) (submittedVersion, other-oa)
- Funders
- Foundation Fighting Blindness (TA-GT-0715-0665-LUMC)
- The Netherlands Organization for Health Research and Development (43200004)
- Million Dollar Bike Ride Grant Program (MDBR-19-131-CRB1, MDBR-20-112-CRB1)
- Dutch blindness funds (Uitzicht 2013-13)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- adeno-associated virus vectors, ocular gene therapy, inherited retinal disease, optic neuropathy, promoter, inverted terminal repeats, biological activity assay, retinal organoids, clinical trials
- MeSH terms
- Dependovirus, Clinical Trials as Topic, Genetic Vectors, Optic Nerve Diseases, Promoter Regions, Genetic, Genetic Therapy, Treatment Outcome, Polyadenylation, Capsid Proteins, Retinal Dystrophies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-01, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-01 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.